Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-70218902 in Metastatic Castration-Resistant Prostate Cancer
NCT04397276Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of JNJ-70218902 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events at 2.5 years, Number of Participants with Dose-Limiting Toxicity at 21 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
JNJ-70218902
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04397276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397276.